Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) Shares Down 6.6% – Here’s Why

Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM)’s stock price fell 6.6% during mid-day trading on Wednesday. The company traded as low as C$0.28 and last traded at C$0.28. Approximately 4,800 shares were traded during mid-day trading, an increase of 68% from the average daily volume of 2,858 shares. The stock had previously closed at C$0.30.

Zomedica Pharmaceuticals Corp. (ZOM.V) Stock Down 6.6%

The stock has a market capitalization of C$36.73 million and a price-to-earnings ratio of -2.61. The firm’s fifty day moving average is C$0.29 and its 200-day moving average is C$0.28. The company has a debt-to-equity ratio of 4.91, a current ratio of 15.31 and a quick ratio of 15.24.

About Zomedica Pharmaceuticals Corp. (ZOM.V)

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination.